Andere Sprachen Axonics, Inc.

Aktien

A2N7B2

US05465P1012

AXNX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 23.04.2024			Vorbörslich 15:29:06
66,47 ^USD	-0,55 %		66,43	-0,06 %

04.04.	MÄRKTE USA/Börsen deutlich im Minus - Warten auf US-Arbeitsmarktbericht	DJ
04.04.	MÄRKTE USA/Wall Street mit Aufschlägen	DJ

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Boston Scientific Announces Results for First Quarter 2024	12:31
Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	04.04.
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	04.04.
FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal	04.04.
Axonics Stockholders Approve Merger Agreement with Boston Scientific	25.03.
Axonics Wins Shareholder Approval of Merger With Boston Scientific	22.03.
Axonics Stockholders Approve Merger Agreement with Boston Scientific	22.03.
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case	21.03.
Axonics Provides Update on Inter Partes Review Proceedings	21.03.
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling	21.03.
Axonics to Sell Rechargeable Sacral Neuromodulation System in Europe Starting April	14.03.
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System	14.03.
North American Morning Briefing : Stock Futures -2-	06.03.
Axonics Responds to ITC Action by Medtronic	29.02.
Axonics Q4 Earnings, Revenue Rise -- Shares Edge Higher After Hours	28.02.
Axonics: Q4 Earnings Snapshot	28.02.
Axonics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28.02.
Earnings Flash (AXNX) AXONICS Posts Q4 Revenue $109.7M	28.02.
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results	28.02.
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Axonics, Inc.

Aktien

A2N7B2

US05465P1012

AXNX

Andere Sprachen

Filter